Alumis Stock: Key Catalysts on the Horizon for 2026

Following its participation in major industry summits, Alumis Inc. is entering a period of heightened investor anticipation. The market's attention is now pivoting toward upcoming regulatory submissions and clinical data readouts scheduled for later this year, as the company advances its lead drug candidates. The central question for shareholders is whether Alumis can deliver on the ambitious goals set for its flagship therapy, Envudeucitinib.

The clinical development pipeline remains a primary focus. Of particular interest are the topline results from the Phase 2b LUMUS trial in systemic lupus erythematosus (SLE). These data are currently expected in the third quarter of 2026.

Concurrently, the regulatory pathway is taking shape. A potential New Drug Application (NDA) for the treatment of moderate-to-severe plaque psoriasis is targeted for the second half of 2026. Successfully filing this application would represent a significant transition for Alumis, moving it toward becoming a commercial-stage biopharmaceutical company.

Should investors sell immediately? Or is it worth buying Alumis?

Near-Term Presentation and Market Context

A key near-term event is the company's scheduled virtual presentation at the Oppenheimer Healthcare Life Sciences Conference in ten days, on February 26, 2026. This forum will likely provide an update on Envudeucitinib, an oral TYK2 inhibitor designed to treat immune-mediated diseases.

The competitive landscape in immunology is increasingly focused on oral therapies that can rival the efficacy of established injectable biologics. For TYK2 inhibitors like Envudeucitinib, achieving commercial success is heavily dependent on demonstrating high selectivity and a favorable safety profile to distinguish themselves in a crowded autoimmune disease market.

With the late-February presentation and the planned data releases in the latter half of the year, Alumis has clear catalysts on the calendar. These events will be critical in assessing Envudeucitinib's potential to secure a position within a highly competitive therapeutic arena.